Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes - PubMed (original) (raw)
Review
Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes
Luca De Nicola et al. Am J Kidney Dis. 2014 Jul.
Abstract
Optimal prevention and treatment of chronic kidney disease in diabetes requires implementing therapies that specifically interfere with the pathogenesis of diabetic nephropathy. In this regard, significant attention has been given to alterations of the proximal tubule and resulting changes in glomerular filtration rate. At the onset of diabetes mellitus, hyperglycemia causes increases in proximal tubular reabsorption secondary to induction of tubular growth with associated increases in sodium/glucose cotransport. The increase in proximal reabsorption leads to a decrease in solute load to the macula densa, deactivation of the tubuloglomerular feedback, and increases in glomerular filtration rate. Because glomerular hyperfiltration currently is recognized as a risk factor for progression of kidney disease in diabetic patients, limiting proximal tubular reabsorption constitutes a potential target to reduce hyperfiltration. The recent introduction of sodium/glucose cotransporter 2 (SGLT2) inhibitors opens new therapeutic perspectives for this high-risk patient population. Experimental studies have shown that these new agents attenuate the progressive nature of diabetic nephropathy by blood glucose-dependent and -independent mechanisms. SGLT2 inhibition may prevent glomerular hyperfiltration independent of the effect of lowering blood glucose levels while limiting kidney growth, inflammation, and albuminuria through reductions in blood glucose levels. Clinical data for the potential role of the proximal tubule in the pathophysiology of diabetic nephropathy and the nephroprotective effects of SGLT2 inhibitors currently are limited compared to the more extensive experimental literature. We review the evidence supporting this working hypothesis by integrating the experimental findings with the available clinical data.
Keywords: Diabetes mellitus (DM); SGLT2 inhibitor; canagliflozin; dapagliflozin; diabetic nephropathy (DN); glomerular filtration rate (GFR); hyperfiltration; proximal tubule; sodium/glucose cotransport; sodium/glucose cotransporter 2 (SGLT2).
Copyright © 2014 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
Similar articles
- Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy.
Škrtić M, Cherney DZ. Škrtić M, et al. Curr Opin Nephrol Hypertens. 2015 Jan;24(1):96-103. doi: 10.1097/MNH.0000000000000084. Curr Opin Nephrol Hypertens. 2015. PMID: 25470017 Review. - SGLT2 Inhibitors and the Diabetic Kidney.
Fioretto P, Zambon A, Rossato M, Busetto L, Vettor R. Fioretto P, et al. Diabetes Care. 2016 Aug;39 Suppl 2:S165-71. doi: 10.2337/dcS15-3006. Diabetes Care. 2016. PMID: 27440829 - The roles of sodium-glucose cotransporter 2 inhibitors in preventing kidney injury in diabetes.
Jaikumkao K, Pongchaidecha A, Chatsudthipong V, Chattipakorn SC, Chattipakorn N, Lungkaphin A. Jaikumkao K, et al. Biomed Pharmacother. 2017 Oct;94:176-187. doi: 10.1016/j.biopha.2017.07.095. Epub 2017 Jul 29. Biomed Pharmacother. 2017. PMID: 28759755 Review. - Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.
Vallon V, Thomson SC. Vallon V, et al. Diabetologia. 2017 Feb;60(2):215-225. doi: 10.1007/s00125-016-4157-3. Epub 2016 Nov 22. Diabetologia. 2017. PMID: 27878313 Free PMC article. Review. - Sodium-glucose cotransporter 2 inhibition in type 1 diabetes: simultaneous glucose lowering and renal protection?
Cherney DZ, Perkins BA. Cherney DZ, et al. Can J Diabetes. 2014 Oct;38(5):356-63. doi: 10.1016/j.jcjd.2014.05.006. Epub 2014 Sep 3. Can J Diabetes. 2014. PMID: 25192954 Review.
Cited by
- BMSCs and miR-124a ameliorated diabetic nephropathy via inhibiting notch signalling pathway.
Sun J, Zhao F, Zhang W, Lv J, Lv J, Yin A. Sun J, et al. J Cell Mol Med. 2018 Oct;22(10):4840-4855. doi: 10.1111/jcmm.13747. Epub 2018 Jul 19. J Cell Mol Med. 2018. PMID: 30024097 Free PMC article. - Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment.
Samsu N. Samsu N. Biomed Res Int. 2021 Jul 8;2021:1497449. doi: 10.1155/2021/1497449. eCollection 2021. Biomed Res Int. 2021. PMID: 34307650 Free PMC article. Review. - Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease.
Zhang Y, Thai K, Kepecs DM, Gilbert RE. Zhang Y, et al. PLoS One. 2016 Jan 7;11(1):e0144640. doi: 10.1371/journal.pone.0144640. eCollection 2016. PLoS One. 2016. PMID: 26741142 Free PMC article. - Relationship between basal sodium intake and the effects of dapagliflozin in albuminuric diabetic kidney disease.
Kinguchi S, Wakui H, Ito Y, Kondo Y, Azushima K, Osada U, Yamakawa T, Iwamoto T, Yutoh J, Misumi T, Yasuda G, Yoshii T, Haruhara K, Kobayashi Y, Yamanaka T, Terauchi Y, Tamura K. Kinguchi S, et al. Sci Rep. 2021 Jan 13;11(1):951. doi: 10.1038/s41598-020-79687-z. Sci Rep. 2021. PMID: 33441623 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical